M
426.04
-5.96 (-1.38%)
| 前收盘价格 | 432.00 |
| 收盘价格 | 430.23 |
| 成交量 | 35,487 |
| 平均成交量 (3个月) | 347,383 |
| 市值 | 9,675,973,632 |
| 预期市盈率 (P/E Forward) | 666.67 |
| 价格/销量 (P/S) | 10.33 |
| 股市价格/股市净资产 (P/B) | 16.79 |
| 52周波幅 | |
| 利润日期 | 30 Apr 2026 |
| 营业毛利率 | -123.38% |
| 营业利益率 (TTM) | -57.79% |
| 稀释每股收益 (EPS TTM) | -17.83 |
| 总债务/股东权益 (D/E MRQ) | 16.85% |
| 流动比率 (MRQ) | 5.91 |
| 营业现金流 (OCF TTM) | -395.31 M |
| 杠杆自由现金流 (LFCF TTM) | -274.11 M |
| 资产报酬率 (ROA TTM) | -25.56% |
| 股东权益报酬率 (ROE TTM) | -50.16% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Madrigal Pharmaceuticals, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
1.3
| 分析师共识 | 5.0 |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -2.0 |
| 平均 | 1.25 |
|
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 7.73% |
| 机构持股比例 | 108.28% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 964.00 (Barclays, 126.27%) | 购买 |
| 中 | 745.00 (74.87%) | |
| 低 | 529.00 (B of A Securities, 24.17%) | 保留 |
| 平均值 | 746.00 (75.10%) | |
| 总计 | 2 购买, 1 保留 | |
| 平均价格@调整类型 | 478.83 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| B of A Securities | 20 Feb 2026 | 529.00 (24.17%) | 保留 | 435.01 |
| Barclays | 28 Jan 2026 | 964.00 (126.27%) | 购买 | 496.54 |
| Citizens | 20 Jan 2026 | 745.00 (74.87%) | 购买 | 504.95 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合